Table 3.
Sensitivity of TRK immunohistochemistry as a screening tool to detect NTRK fusions, according to published studies.
| Study | Sensitivity (n) a | |||||||
|---|---|---|---|---|---|---|---|---|
| NTRK1 | NTRK2 | NTRK3 | Overall | |||||
| Hechtman 2017 [15] | 100 | (10/10) | 100 | (2/2) | 88.9 | (8/9) | 95.2 | (21/22) |
| Murphy 2017 [25] | Affected NTRK genes not specified | 100 | (8/8) | |||||
| Rudzinski 2018 [24] | 100 | (12/12) | 100 | (1/1) | 94.1 | (16/17) | 96.7 | (29/30) |
| Solomon 2019 [26] | 96.2 | (26/27) | 100 | (5/5) | 79.4 | (27/34) | 87.9 | (58/66) |
| Gatalica 2019 [27] | 87.5 | (7/8) | 88.9 | (8/9) | 54.5 | (6/11) | 75.0 | (21/28) |
| Current study | 86 | (13/15) | 100 | (2/2) | 67 | (8/12) | 79.3 | (23/29) |
a For each gene, the first column displays sensitivity (in %), and the second column displays the absolute division (a/b) used to calculate sensitivity, using the number of patients with NTRK fusions (b) that tested positive with TRK immunohistochemistry (a).